Provided by Tiger Trade Technology Pte. Ltd.

Provident

20.73
-0.1900-0.91%
Volume:30.12K
Turnover:623.51K
Market Cap:2.71B
PE:9.30
High:20.75
Open:20.75
Low:20.68
Close:20.92
52wk High:23.98
52wk Low:14.34
Shares:130.62M
Float Shares:126.13M
Volume Ratio:0.43
T/O Rate:0.02%
Dividend:0.96
Dividend Rate:4.63%
EPS(TTM):2.23
EPS(LYR):2.23
ROE:10.72%
ROA:1.19%
PB:0.96
PE(LYR):9.29

Loading ...

Venus Metals to launch PFS over WA Sandstone gold project

The West Australian
·
Dec 29, 2025

Three Prominent Dividend Stocks To Consider For Your Portfolio

Simply Wall St.
·
Dec 27, 2025

Lung Cancer Frontline! "Furmonertinib" New Indication Proposed for Breakthrough Therapy Designation

Deep News
·
Dec 26, 2025

Top Dividend Stocks To Consider In December 2025

Simply Wall St.
·
Dec 25, 2025

3 Top Dividend Stocks To Consider

Simply Wall St.
·
Dec 24, 2025

Kalamazoo locks in project lead for WA gold prefeasibility study

The West Australian
·
Dec 24, 2025

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

GlobeNewswire
·
Dec 22, 2025

3 Dividend Stocks To Enhance Your Portfolio

Simply Wall St.
·
Dec 18, 2025

Provident Financial Services Inc. Appoints New Executives and Promotes Key Leaders

Reuters
·
Dec 17, 2025

Press Release: Provident Bank Announces New Hires and Promotions

Dow Jones
·
Dec 17, 2025

Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers

GlobeNewswire
·
Dec 17, 2025

Junshi Biosciences Files for Hong Kong IPO: Core Product Shows Modest Data with Pending Patents, Pre-Listing Shareholder Repurchase Demands Raise Concerns

Deep News
·
Dec 17, 2025

FDA Approves Enhertu Combination Therapy for First-Line HER2-Positive Breast Cancer Treatment

Deep News
·
Dec 16, 2025

Did Gedatolisib’s Phase 3 PFS and Tolerability Data Just Shift Celcuity’s (CELC) Investment Narrative?

Simply Wall St.
·
Dec 16, 2025

Dividend Stocks To Consider In December 2025

Simply Wall St.
·
Dec 12, 2025

InnoCare Announces Approval of the Next-Generation TRK Inhibitor Zurletrectinib in China

GlobeNewswire
·
Dec 11, 2025

High-Grade Sandstone Hub Drilling And PFS Progress Could Be A Game Changer For Brightstar Resources (ASX:BTR)

Simply Wall St.
·
Dec 10, 2025

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

GlobeNewswire
·
Dec 09, 2025

Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+ in patients with first line advanced melanoma

GlobeNewswire
·
Dec 09, 2025

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

GlobeNewswire
·
Dec 09, 2025